Karyopharm Therapeutics Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the supplied text does not provide standalone fourth-quarter results.
Business context
Karyopharm is a commercial-stage oncology company whose lead product, XPOVIO (selinexor), is approved in the U.S. for three cancer indications: multiple myeloma in combination regimens and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Partners commercialize selinexor in markets outside the U.S.; it had approvals in more than 40 countries. The company’s priority pipeline programs are multiple myeloma, endometrial cancer and myelofibrosis (MF).
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $146.0 million | $157.1 million |
| U.S. net product revenue | $112.0 million | $120.4 million |
| License and other revenue | $34.0 million | $36.6 million |
| Research and development expense | $138.8 million | $148.7 million |
| Selling, general and administrative expense | $131.9 million | $145.4 million |
| Operating loss | $129.5 million | $142.2 million |
| Net loss | $143.1 million | $165.3 million |
| Net cash used in operating activities | $92.7 million | $149.6 million |
| Cash, cash equivalents and investments at year-end | $191.4 million | $278.0 million |
Product revenue fell 7%, primarily reflecting increased use of the company’s patient assistance program after multiple myeloma foundations that support Medicare Part D patients closed. Karyopharm estimated this reduced 2023 revenue by approximately $5.8 million. License revenue decreased 7%, principally because of lower Antengene milestone and royalty revenue, partly offset by higher Menarini revenue, including $15.0 million of development-cost reimbursements.
Operating expenses declined 8% year over year. Lower personnel, stock-based compensation and commercial-related costs more than offset higher clinical trial costs. The reduced operating cash outflow reflected lower expenses and $27.3 million of Antengene milestone receipts. The company reported a $1.5 billion accumulated deficit and negative stockholders’ equity of $136.2 million at year-end.
Year-end current assets were $233.9 million and current liabilities were $69.5 million. Debt and royalty financing included $172.5 million principal amount of 3.00% convertible notes due October 2025 (carrying value $170.9 million) and a $132.5 million reported deferred royalty obligation. The notes require $182.9 million of scheduled payments through maturity; future HCR royalty obligations were estimated at approximately $201.6 million.
Material developments, outlook and risks
- Management stated that year-end cash, cash equivalents and investments were expected to fund current operating and capital expenditure plans for at least 12 months from the financial statements’ issuance. Karyopharm expects to continue needing additional financing and does not expect to achieve profitability in the near term.
- For 2024, management expected revenue from license and other sources to increase, primarily due to expected milestone achievements; R&D expense to increase slightly as three pivotal Phase 3 trials advance; SG&A expense to decrease slightly through cost optimization; and cost of sales and other expense, net to remain relatively consistent.
- In January 2024, the company placed further clinical development of eltanexor on hold to concentrate resources on prioritized later-stage programs. The Phase 3 EC-042 study in TP53 wild-type endometrial cancer experienced EU site-activation delays related to new diagnostic-device requirements.
- Selinexor’s DLBCL indication remains under accelerated approval, with continued approval potentially dependent on confirming clinical benefit. The company also relies on third-party manufacturers, including a single-source supplier for active ingredient and drug-product manufacturing.
- Key risks include continued losses and financing needs, competition and reimbursement pressure, adverse effects and trial or regulatory setbacks, debt and HCR agreement obligations, and potential dilution from future equity issuance. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
Investor verification priorities
- Track XPOVIO product sales, net pricing and patient-assistance-program use, including whether the expected 2024 Medicare Part D changes reduce assistance-related revenue pressure.
- Verify progress, enrollment and timelines for the three pivotal Phase 3 programs, the EC-042 diagnostic and EU activation, and the DLBCL confirmatory study.
- Assess cash runway against operating cash burn, expected milestone receipts and the company’s stated need for further financing.
- Review the October 2025 convertible-note maturity, HCR payment and covenant terms, and the potential for refinancing, dilution or accelerated obligations.
- Confirm the timing and probability of anticipated partner milestones and royalties; these are contingent and are not assured revenue.